Oryzon Doses First Patient In Yale-Led Phase Ib Trial For ES-SCLC Combination, Iadademstat Tested With Radiation And Atezolizumab In Recurrent Small Cell Lung Cancer

Oryzon Genomics announced that the first patient has been treated in a Phase Ib clinical trial led by Yale University, testing iadademstat, its selective LSD1 inhibitor, in combination with radiotherapy and the immune checkpoint inhibitor atezolizumab in patients with extensive-stage small cell lung cancer (ES-SCLC). The study focuses on individuals whose disease has persisted, progressed or returned after first-line treatment.

Dr. Carlos Buesa, Oryzon’s CEO, stated: “The initiation of this investigator-led study at Yale University represents an important milestone in our efforts to expand the clinical development of iadademstat in small cell lung cancer. Combining LSD1 inhibition with immunotherapy and radiotherapy is a compelling strategy, and we look forward to the insights this trial may provide into the potential role of iadademstat in addressing this aggressive disease with high unmet medical need.” 

The investigator-initiated trial (NCT07113691) is an open-label, non-randomised, dose-finding study designed to assess the safety, tolerability and early signs of efficacy of the three-drug regimen. Patients will receive iadademstat alongside atezolizumab and stereotactic body radiation therapy (SBRT), followed by maintenance treatment with both drugs.

Dr. Chiang, Principal Investigator of the study, added: “Some SCLC patients have had long-term benefit with immunotherapy, and we hope to learn how to extend the benefit to more people. Through this study, we aim to enhance the immune response by combining radiation and iadademstat with immunotherapy in SCLC patients. The use of paired biopsies will help us understand key events that are occurring in the tumour and its microenvironment as well.”

Eligible participants are those who have previously received platinum-based chemotherapy, with or without prior checkpoint inhibitor therapy. The trial is being conducted at Yale University, with Dr. Anne Chiang serving as principal investigator.